On May 22, 2025, analyst Raghuram Selvaraju from HC Wainwright & Co. reiterated a "Neutral" rating for Sarepta Therapeutics (SRPT, Financial). The rating remains unchanged from the prior assessment.
The price target for Sarepta Therapeutics (SRPT, Financial) continues to be set at $40.00 USD, maintaining the previous valuation. This decision reflects no percentage change in the adjusted price target since the preceding review.
Sarepta Therapeutics (SRPT, Financial), trading on the NASDAQ, has its outlook consistently maintained by HC Wainwright & Co., with no significant alterations in the analyst's perspective.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Sarepta Therapeutics Inc (SRPT, Financial) is $96.75 with a high estimate of $185.00 and a low estimate of $40.00. The average target implies an upside of 141.57% from the current price of $40.05. More detailed estimate data can be found on the Sarepta Therapeutics Inc (SRPT) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, Sarepta Therapeutics Inc's (SRPT, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sarepta Therapeutics Inc (SRPT, Financial) in one year is $270.35, suggesting a upside of 575.03% from the current price of $40.05. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sarepta Therapeutics Inc (SRPT) Summary page.
